Pancreatic Cancer Research

ResearcherGuy's HospitalActive in the last 2 years

Paul J. Ross

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2390-1886; OpenAlex author ID A5084034524. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 1, last author 0)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
0
Collaborators
68
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: none · 2013: none · 2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 2 papers, 1 trial · 2018: none · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper, 1 trial · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 11

  1. Vanishing liver metastases in pancreatic cancer: A case report. First author DOI 10.3892/ol.2026.15691↗
  2. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  3. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  4. Results of a single-arm pilot study of 32P microparticles in unresectable locally advanced pancreatic adenocarcinoma with gemcitabine/nab-paclitaxel or FOLFIRI… Co-author DOI 10.1016/j.esmoop.2021.100356↗
  5. Margin ACcentuation for resectable Pancreatic cancer using Irreversible Electroporation - Results from the MACPIE-I study. Co-author DOI 10.1016/j.ejso.2021.05.024↗
  6. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  7. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Co-author DOI 10.1007/s11523-016-0469-y↗
  8. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… Co-author DOI 10.1016/s0140-6736(16)32409-6↗
  9. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  10. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an … Co-author DOI 10.1016/s1470-2045(14)70236-0↗
  11. FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer. Co-author DOI 10.1586/14737140.2014.957188↗

Trials 3

  1. OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry. Principal investigator NCT04493632↗
  2. A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane Principal investigator NCT03003078↗
  3. 32P BioSiliconTM in Addition to Gemcitabine in Pancreatic Cancer Principal investigator NCT00346281↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andreas A. Prachalias · 3 shared papers, 2021–2026 · strength 0.66
  2. Harpreet Singh Wasan · 5 shared papers, 2017–2025 · strength 0.52
  3. Evangelia Florou · 1 shared paper, 2026 · strength 0.43
  4. John P. Neoptolemos · 5 shared papers, 2014–2025 · strength 0.42
  5. David Cunningham · 5 shared papers, 2014–2025 · strength 0.42
  6. Juan W. Valle · 5 shared papers, 2014–2025 · strength 0.42
  7. Yuk Ting Ma · 4 shared papers, 2017–2025 · strength 0.39
  8. Paula Ghaneh · 4 shared papers, 2017–2025 · strength 0.39
  9. Daniel H. Palmer · 4 shared papers, 2017–2025 · strength 0.39
  10. Thilo Hackert · 4 shared papers, 2017–2025 · strength 0.39
  11. Christopher Michael Halloran · 4 shared papers, 2017–2025 · strength 0.39
  12. Gary Middleton · 4 shared papers, 2014–2025 · strength 0.30
  13. Christoph Springfeld · 2 shared papers, 2023–2025 · strength 0.29
  14. Olusola Olusesan Faluyi · 3 shared papers, 2017–2025 · strength 0.27
  15. Bengt L. G. Glimelius · 3 shared papers, 2017–2025 · strength 0.27
  16. Tim Meyer · 3 shared papers, 2017–2025 · strength 0.27
  17. Pascal R. Hammel · 3 shared papers, 2017–2025 · strength 0.27
  18. Markus Wolfgang Büchler · 3 shared papers, 2017–2023 · strength 0.22
  19. Derek A O'Reilly · 3 shared papers, 2017–2023 · strength 0.22
  20. Peter J. Bailey · 1 shared paper, 2025 · strength 0.17
  21. Christoph W. Michalski · 1 shared paper, 2025 · strength 0.17
  22. Debashis Sarker · 2 shared papers, 2014–2021 · strength 0.17
  23. Alan Anthoney · 3 shared papers, 2014–2019 · strength 0.13
  24. Nam Quoc Nguyen · 1 shared paper, 2022 · strength 0.13
  25. Adnan M. Nagrial · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.